Conclusion
SARS-CoV-2 infection
SARS-COV-2 INFECTION
Based on phase I and II clinical trials of DC–based COVID-19 prevention vaccines, the absence of SAE associated with vaccine administration for up to 1 year for SARS-CoV-2 infection shows good tolerability and safety. Of the three vaccine dose candidates tested, the smallest dose of 0.1 mcg provides good immunogenicity and is supported by minimal AE. A 1-year evaluation shows that this vaccine appears to have long-term immunogenic potential. The phase III trial with a larger number of subjects is needed to ensure the efficacy of this vaccine and see other possible side effects.